Ponatinib

Conditions Treated

Ponatinib is used to treat certain types of blood and bone marrow cancers in adults. It is specifically indicated for:

• Chronic Myeloid Leukemia (CML): This includes the chronic phase, accelerated phase, and blast phase of the disease.
• Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): A specific type of fast-growing leukemia.

Clinical Use Cases

This medication is typically used in the following circumstances:

• When a patient has a specific genetic mutation called T315I, which makes the leukemia resistant to many other common treatments.
• When other treatments, such as other kinase inhibitors, have not worked or are no longer effective.
• When a patient cannot tolerate other treatments due to severe side effects.
• When no other kinase inhibitor treatment is considered appropriate by a healthcare provider.

Targeting Cancer Proteins

Ponatinib belongs to a class of drugs called tyrosine kinase inhibitors (TKIs). It is designed to target an abnormal protein known as BCR-ABL. This protein is found in patients with certain types of blood cancer, including chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

In these conditions, a genetic change causes the body to produce the BCR-ABL enzyme, which acts like a switch that is permanently stuck in the "on" position. This sends continuous signals to white blood cells to divide and grow uncontrollably. Ponatinib works by binding to this protein and blocking its activity, which helps to:

• Slow or stop the production of abnormal leukemia cells.
• Prevent the cancer from spreading further in the blood and bone marrow.
• Encourage the death of existing cancer cells.

Overcoming Treatment Resistance

Cancer cells can sometimes develop mutations that make them resistant to standard treatments. Ponatinib is specifically engineered to remain effective even when a common mutation called T315I is present. This mutation changes the shape of the BCR-ABL protein, preventing many other kinase inhibitors from binding to it. Ponatinib is designed to bypass this structural change, allowing it to continue blocking the growth signals even in resistant cases.

Common Side Effects

• Skin rash, dry skin, or itching
• Fatigue or unusual weakness
• Headache
• Stomach pain, nausea, or vomiting
• Constipation or diarrhea
• Joint, muscle, or bone pain
• Fever

Serious Side Effects

Seek medical attention immediately if you experience any of the following serious symptoms:

• Cardiovascular problems: Chest pain, shortness of breath, sudden numbness or weakness (especially on one side of the body), slurred speech, or pain and swelling in the legs.
• Liver toxicity: Yellowing of the skin or eyes (jaundice), dark urine, or pain in the upper right stomach area.
• Pancreatitis: Severe pain in the upper stomach that may spread to the back.
• High blood pressure: Severe headache, dizziness, or changes in vision.
• Bleeding: Unusual bruising, nosebleeds, or blood in the stool or urine.
• Fluid retention: Rapid weight gain or swelling of the hands, ankles, or feet.

Ponatinib may also interfere with the body's ability to heal wounds. It is important to notify your healthcare provider about any upcoming surgeries or dental procedures, as the medication may need to be temporarily stopped.

Boxed Warnings

Ponatinib includes boxed warnings for the following serious conditions:

• Arterial Occlusive Events: Serious and sometimes fatal blood clots in the arteries can occur, leading to heart attacks, strokes, or severely decreased blood flow to the limbs. These events have occurred in patients with and without traditional cardiovascular risk factors.
• Venous Thromboembolic Events: Blood clots in the veins, such as deep vein thrombosis or pulmonary embolism, have been reported.
• Heart Failure: This medication can cause new or worsening heart failure, which may be fatal. Cardiac function should be monitored regularly during treatment.
• Hepatotoxicity: Severe liver damage, including liver failure and death, has occurred. Liver function tests are typically performed before starting treatment and periodically thereafter.

Other Serious Precautions

Additional warnings and precautions include:

• Hypertension: Significant increases in blood pressure can occur, including hypertensive crisis. Blood pressure should be monitored at every clinic visit.
• Pancreatitis: Inflammation of the pancreas is a known risk. Healthcare providers usually monitor lipase levels frequently, especially during the first few months of treatment.
• Hemorrhage: Severe or fatal bleeding events have been reported in patients taking this medication.
• Fluid Retention: Patients may experience swelling (edema), fluid around the lungs (pleural effusion), or fluid around the heart (pericardial effusion).
• Gastrointestinal Perforation: This medication may cause holes in the stomach or intestines, which can be life-threatening.
• Cardiac Arrhythmias: Irregular heartbeats, such as atrial fibrillation or bradycardia, may occur.
• Tumor Lysis Syndrome: Rapid breakdown of cancer cells can lead to kidney failure and dangerous electrolyte imbalances.
• Impaired Wound Healing: Ponatinib may interfere with the body's ability to heal wounds. It is typically discontinued for a period of time before and after major surgical procedures.
• Embryo-Fetal Toxicity: This drug can cause fetal harm when administered to a pregnant woman. Effective contraception is recommended for patients of reproductive potential during treatment and for a period after the final dose.

Pregnancy

Ponatinib may cause fetal harm when administered to a pregnant person. Animal studies have indicated that the medication can lead to birth defects or pregnancy loss. Healthcare providers typically require a pregnancy test before starting treatment to ensure the patient is not pregnant.

Individuals of reproductive potential should use effective birth control during treatment and for at least 3 weeks after the final dose. If a patient becomes pregnant or thinks they might be pregnant while taking this medication, they should contact their healthcare provider immediately to discuss the potential risks to the fetus.

Breastfeeding

It is not known whether ponatinib passes into human breast milk. Because of the potential for serious adverse reactions in a nursing infant, breastfeeding is not recommended during treatment and for at least 6 days after the last dose.

Fertility

Based on animal data, ponatinib may impair fertility in females. This could affect the ability to become pregnant in the future. Patients should discuss family planning and any concerns regarding fertility with their healthcare team before beginning treatment.

Dosage Forms

Ponatinib is available as a film-coated tablet for oral administration.

Administration

The tablets are intended to be swallowed whole. They should not be crushed, chewed, or broken before ingestion.

FDA Approval and Indications

Ponatinib was first approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It is typically reserved for patients who have the T315I mutation or those for whom other kinase inhibitor therapies are not suitable.

In March 2024, the FDA granted accelerated approval for ponatinib to be used in combination with chemotherapy for adults with newly diagnosed Ph+ ALL. Continued approval for this specific use may depend on the results of ongoing clinical trials.

Boxed Warning

The FDA has issued a Boxed Warning for ponatinib, which is the most serious type of warning for a medication. This warning highlights the following risks:

• Arterial Occlusive Events: Serious and life-threatening blood clots or narrowing of the arteries, which can lead to heart attack, stroke, or decreased blood flow to the limbs.
• Venous Thromboembolic Events: Blood clots in the veins, such as deep vein thrombosis or pulmonary embolism.
• Heart Failure: The medication may cause the heart to weaken or fail.
• Hepatotoxicity: Severe liver damage, liver failure, or death has occurred in some patients.

Regulatory History

In late 2013, the FDA briefly suspended the marketing and sales of ponatinib due to reports of an increased frequency of blood clots and narrowing of blood vessels. After a safety review, the drug was allowed back on the market with revised labeling, a Boxed Warning, and more restrictive indications to ensure it is used primarily by patients who have few other treatment options.

FDA Indications

The FDA has approved ponatinib for the treatment of adults with the following conditions:

• Chronic myeloid leukemia (CML) in the chronic, accelerated, or blast phases.
• Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

It is specifically indicated for patients whose cancer is resistant or intolerant to prior kinase inhibitor therapy, or for those who have the T315I mutation. Because of its risks, it is often used when no other tyrosine kinase inhibitor (TKI) therapy is appropriate.

FDA Boxed Warnings

The FDA requires a boxed warning for ponatinib because it can cause serious and life-threatening side effects. These include:

• Vascular Occlusion: Serious blood clots in the arteries and veins, which may lead to heart attack, stroke, or loss of blood flow to the limbs. These events have occurred in patients with and without cardiovascular risk factors.
• Heart Failure: The medication can cause the heart muscle to weaken or fail, which may be fatal.
• Hepatotoxicity: Ponatinib can cause severe liver damage, liver failure, and death. Liver function must be monitored before and during treatment.

Approval History

Ponatinib received accelerated approval from the FDA in December 2012. Due to the high risk of serious side effects, the FDA has established specific monitoring requirements for patients using this drug, including regular assessments of cardiovascular health and liver function.